EC-Botanics-Germanys-legalisation-of-cannabis
|

Germany’s legalisation of cannabis | ECS Botanics

“Perth-headquartered medicinal cannabis company Little Green Pharma (LGP) is bullish on opportunities in Germany after the country legalised the drug on Friday with certain limitations, including personal possession of up to 25g, allowing three marijuana plants per household, and the establishment of non-commercial clubs for cultivation and distribution with caps on membership and volume.” Read…

ECS Botanics: Organic Medicinal Cannabis – Investor Webinar Recap
|

ECS Botanics: Organic Medicinal Cannabis – Investor Webinar Recap

Introduction ECS Botanics Holding Ltd., a leading name in the organic cultivation and manufacturing of GMP medicinal cannabis products, recently hosted an insightful investor webinar. This event provided a comprehensive overview of the company’s operations, strategic initiatives, and future growth prospects. Here’s a detailed recap of the key points discussed during the webinar. Webinar Highlights…

Australian Cannabis Companies – top 20
|

Australian Cannabis Companies – top 20

Australian Cannabis Companies 2022 – top 20 list Whether it’s a “gold rush” to secure registration for selling over-the-counter at chemists, proactive outreach to get clinicians on side, or pocket-emptying, long-game research requiring patience and patients at a pharmaceutical level, medicinal cannabis is an industry that attracts all stripes. Against the backdrop of a global…

ECS Botanics will supply cannabis biomass to Sun Pharma to produce resin under a 10-year deal
|

ECS Botanics inks cannabis supply and tolling deal with Sun Pharma

Medicinal cannabis and hemp company ECS Botanics Holdings (ASX: ECS) has revealed it has entered into a collaborative supply and toll processing agreement for cannabis biomass extraction with pharmaceutical company Sun Pharma. Sun Pharma is an Australia-based subsidiary of Sun Pharmaceutical Industries, the fourth largest specialty generic pharmaceutical company in the world. With global revenues in excess…